KMID : 1130320100530040565
|
|
Korean Journal of Pediatrics 2010 Volume.53 No. 4 p.565 ~ p.570
|
|
Clinical efficacy and safety of lamotrigine monotherapy in newly diagnosed pediatric patients with epilepsy
|
|
Han Ji-Hye
Oh Jeung-Eun Kim Sun-Jun
|
|
Abstract
|
|
|
Purpose: To verify the efficacy and safety of lamotrigine (LTG) monotherapy in newly diagnosed children with epilepsy.
Methods: We prospectively enrolled 148 children who had undergone LTG monotherapy at our institution between September 2002 and June 2009. Twenty-nine patients were excluded: 19 due to incomplete data and 10 were lost to follow up. The data of the remaining 119 patients was analyzed.
Results: We enrolled 119 pediatric epilepsy patients (aged 2.8-19.3 years; 66 males and 53 females) in this study. Out of 119 patients, 29 (25.2%) had generalized epilepsy and 90 (74.8%) had partial epilepsy. The responses of seizure reduction were as follows: Seizure freedom (no seizure attack for at least 6 months) in 87/111 (78.4%, n=111) patients; partial response (reduced seizure frequency compared to baseline) in 13 (11.7%) patients; and persistent seizure in 11 (9.9%) patients. The seizure freedom rate was in 81.6% in patients with partial seizure (75.9% for complex partial seizure and 90.9% for benign rolandic epilepsy) and 44.8% in patients with generalized epilepsy (30.0% for absence seizure, 35.7% for juvenile myoclonic epilepsy patients, and 100.0% for idiopathic generalized epilepsy patients). Adverse reactions were reported in 17 (14.3%) patients, and 8 patients (6.7%) discontinued LTG because of rash and tic. No patient experienced severe adverse reaction such as Stevens-Johnson syndrome.
Conclusion: LTG showed excellent therapeutic response and had few significant adverse effects. Our findings report may contribute in promoting the use of LTG monotherapy in epileptic children.
|
|
KEYWORD
|
|
Lamotrigine, Efficacy, Safety, Epilepsy, Child
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|